Purpose of Review <p>To review the current data informing patient selection and provide guidance on when to refer potential patients for consideration of renal denervation.</p> Recent Findings <p>Multiple sham-controlled randomized trials have demonstrated favorable safety and efficacy outcomes for renal denervation (RDN) in the management of uncontrolled hypertension in patients across the hypertension (HTN) spectrum including patients with true resistant hypertension (TRH) and in patients both on and off antihypertensive therapy. In addition, sustained reductions in BP up to 3&#xa0;years have been observed. Based on these favorable findings, guidelines and position papers recommend RDN as an adjunct to antihypertensive medications and lifestyle modifications in patients with uncontrolled hypertension and increased risk of cardiovascular (CV) complications like TRH patients and in patients who are unable or unwilling to optimize medical therapy for uncontrolled hypertension. However, data on RDN safety and efficacy remain limited in chronic kidney disease (CKD) and isolated systolic hypertension (ISH). Another area of active investigation is the identification of predictors of response to RDN which could help refine criteria for patient selection. Selection of patients for RDN requires an evaluation of the hypertension prior to referral in addition to engaging patients in shared decision-making (SDM). It is also recommended that patients being considered for RDN be evaluated by a multidisciplinary team who is knowledgeable about hypertension and RDN.</p> Summary <p>RDN is an adjunct to lifestyle modification and medications for the treatment of hypertension. Appropriate patient selection for RDN is based on populations studied in clinical trials and should include a comprehensive evaluation of the uncontrolled hypertension prior to referral.</p>